In this issue:
Dupilumab in elderly patients with AD
Dupilumab for intractable prurigo
Ustekinumab for AD
Brodalumab for moderate-to-severe plaque psoriasis
Risankizumab for moderate-to-severe plaque psoriasis
PASI response and work productivity with risankizumab
TNF inhibitors and risk COVID-19
Ixekizumab for genital psoriasis
Please login below to download this issue (PDF)